Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors

Advances in Experimental Medicine and Biology

Volumn 524, Issue , 2003, Pages 263-279

  Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

APOPTOSIS; CELL MATURATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME INHIBITION; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; INSULIN RELEASE; INSULIN SYNTHESIS; INTESTINE MUCOSA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRIENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SATIETY; SENSORY NERVE CELL; SMALL INTESTINE; STEM CELL;

ANTIGENS, CD26; APPETITE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN PRECURSORS;

EID: 0038363769     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (88)

1. Bell, G.I., Sanchez-Pescador, R., Laybourn, P.J., Najarian, R.C., 1983, Exon duplication and divergence in the human preproglucagon gene. Nature, 304(5924):368-371.
2. Mojsov, S., Heinrich, G., Wilson, I.B., Ravazzola, M., Orci, L., Habener, J.F., 1986, Preproglucagon gene expression in pancreas and intestine diversifies at the level of posttranslational processing. J Biol Chem, 261(25):11880-11889.
3. Orskov, C., Holst, J.J., Knuhtsen, S., Baldissera, F.G., Poulsen, S.S., Nielsen, O.V., 1986, Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology, 119(4):1467-1475.
4. Drucker, D.J., Erlich, P., Asa, S.L., Brubaker, P.L., 1996, Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A, 93(15):7911-7916.
5. Hartmann, B., Thulesen, J., Hare, K.J., Kissow, H., Orskov, C., Poulsen, S.S., et al., 2002, Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept, 105(3):173-179.
6. Holst, J.J., 1999, Glucagon-like Peptide 1(GLP-1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab, 10(6):229-234.
7. Orskov, C., Wettergren, A., Holst, J.J., 1996, Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol, 31(7):665-670.
8. Miholic, J., Orskov, C., Holst, J.J., Kotzerke, J., Meyer, H.J., 1991, Emptying of the gastric substitute, glucagon-like peptide-1 (GLP- 1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci, 36(10):1361-1370.
9. Toft-Nielsen, M., Madsbad, S., Holst, J.J., 1998, Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia, 41(10):1180-1186.
10. Toft-Nielsen, M., Madsbad, S., Holst, J.J., 1996, The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes, 45(5):552-556.
11. Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P.N., Holst, J.J., 2000, Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am J Physiol, 278(6): E1010-E1018.
12. Fehmann, H.C., Goke, R., Goke, B., 1995, Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev, 16(3):390-410.
13. Weir, G.C., Mojsov, S., Hendrick, G.K., Habener, J.F., 1989, Glucagonlike peptide 1 (7-37) actions on endocrine pancreas. Diabetes, 38(3):338-342.
14. Thorens, B., 1992, Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A, 89(18):8641-8645.
15. Thorens, B., Porret, A., Buhler, L., Deng, S.P., Morel, P., Widmann, C., 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin- (9-39) an antagonist of the receptor. Diabetes, 42(11):1678-1682.
16. Fehmann, H.C., Goke, R., Goke, B., 1995, Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev, 16(3):390-410.
17. Gromada, J., Holst, J.J., Rorsman, P., 1998, Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch, 435(5):583-594.
18. Holz, G.G., Kuhtreiber, W.M., Habener, J.F., 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature, 361(6410):362-365.
19. Gromada, J., Dissing, S., Bokvist, K., Renstrom, E., Frokjaer Jensen, J., Wulff, B.S., et al., 1995, Glucagon-like peptide I increases cytoplasmic calcium in insulin- secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes, 44(7):767-774.
20. Qualmann, C., Nauck, M.A., Holst, J.J., Orskov, C., Creutzfeldt, W., 1995, Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol, 32(1):13-16.
21. Fehmann, H.C., Habener, J.F., 1992, Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology, 130(1):159-166.
22. Buteau, J., Roduit, R., Susini, S., Prentki, M., 1999, Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia, 42(7):856-864.
23. Xu, G., Stoffers, D.A., Habener, J.F., Bonner-Weir, S., 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 48(12):2270-2276.
24. Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Drucker, D.J., Bonnet-Weir, S., Habener, J.F., et al., 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes, 49(5):741-748.
25. Zhou, J., Wang, X., Pineyro, M.A., Egan, J.M., 1999, Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes, 48(12): 2358-2366.
26. Perfetti, R., Zhou, J., Doyle, M.E., Egan, J.M., 2000, Glucagon-like peptide-1 induces cell proliferation and pancreatic- duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 141(12):4600-4605.
27. Bregenholt, S., Moldrup, A., Blume, N., Knudsen, L.B., Petersen, J.S., 2001, The GLP-1 analogue, NN2211, inhibits free fatty acid induced apoptosis in primary rat beta cells. Diabetologia, 44[suppl. 1]: A19.
28. Bregenholt, S., Moldrup, A., Knudsen, L.B., Petersen, J.S., 2001, The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat beta cells. Diabetes, 50[suppl.2]: A31.
29. Bonner-Weir, S., 2000, Life and death of the pancreatic beta cells. Trends Endocrinol Metab, 11(9):375-378.
30. Sturis, J., Jappe, M.B., Knudsen, L.B., Wilken, M., Gjedsted, A., Primdahl, S., et al., 2000, Long-acting GLP-1 derivative NN2211 markedly attenuates diabetes development in the male Zucker fatty rat. Diabetologia, 43 [suppl. 1]: A145.
31. Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., et al., 1998, Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes, 47(3):358-364.
32. Orskov, C., Holst, J.J., Nielsen, O.V., 1988, Effect of truncated glucagon-like peptide-1 [proglucagon-(78- 107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology, 123(4):2009-2013.
33. Orskov, C., Poulsen, S.S., 1991, Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes, 40(10):1292-1296.
34. Heller, R.S., Kieffer, T.J., Habener, J.F., 1997, Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes, 46(5):785-791.
35. Nauck, M.A., Heimesaat, M.M., Behle, K., Holst, J.J., Nauck, M.S., Ritzel, R., et al., 2002, Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab, 87(3):1239-1246.
36. Creutzfeldt, W.O., Kleine, N., Willms, B., Orskov, C., Holst, J.J., Nauck, M.A., 1996, Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care, 19(6):580-586.
37. Hvidberg, A., Nielsen, M.T., Hilsted, J., Orskov, C., Holst, J.J., 1994, Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism, 43(1):104-108.
38. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J., Holst, J.J., 1993, Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci, 38(4):665-673.
39. Nauck, M.A., Niedereichholz, U., Ettler, R., Holst, J.J., Orskov, C., Ritzel, R., et al., 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol, 273(5 Pt 1):E981-E988.
40. Holst, J.J., 1997, Enteroglucagon. Annu Rev Physiol, 59:257-71:257-271.
41. Layer, P., Holst, J.J., Grandt, D., Goebell, H., 1995, Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci, 40(5):1074-1082.
42. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J., Holst, J.J., 1993, Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci, 38(4):665-673.
43. Layer, P., Holst, J.J., Grandt, D., Goebell, H., 1995, Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci, 40(5): 1074-1082.
44. Young, A., Denaro, M., 1998, Roles of amylin in diabetes and in regulation of nutrient load. Nutrition, 14(6):524-527.
45. Read, N., French, S., Cunningham, K., 1994, The Role of the Gut in Regulation Food Intake in Man. Nutrition Reviews, 52(1):1-10.
46. Flint, A., Raben, A., Astrup, A., Holst, J.J., 1998, Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. J Clin Invest, 101(3):515-520.
47. Gutzwiller, J.P., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., et al., 1999, Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 44(1):81-86.
48. Naslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J.E., Holst, J.J., et al., Energy intake and appetite is supressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes. In press.
49. Gutzwiller, J.P., Drewe, J., Goke, B., Schmidt, H., Rohrer, B., Lareida, J., et al., 1999, Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol, 276(5 Pt 2):R1541-R1544.
50. Verdich, C., Flint, A., Gutzwiller, J.P., Naslund, E., Beglinger, C., Hellstrom, P.M., et al., 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab, 86(9):4382-4389.
51. Turton, M.D., O'Shea, D., Gunn, I., Beak, S.A., Edwards, C.M., Meeran, K., et al., 1996, A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature, 379(6560):69-72.
52. Tang-Christensen, M., Larsen, P.J., Goke, R., Fink-Jensen, A., Jessop, D.S., Moller, M., et al., 1996, Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol, 271(4 Pt 2):R848-R856.
53. Goke, R., Larsen, P.J., Mikkelsen, J.D., Sheikh, S.P., 1995, Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci, 7(11):2294-2300.
54. Tang-Christensen, M., Vrang, N., Larsen, P.J., 1998, Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes, 47(4):530-537.
55. Larsen, P.J., Tang-Christensen, M., Holst, J.J., Orskov, C., 1997, Distribution of glucagon-like peptide-1 and other preproglucagon- derived peptides in the rat hypothalamus and brainstem. Neuroscience, 77(1):257-270.
56. Rinaman, L., 1999, Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol, 277(2 Pt 2):R582-R590.
57. Rinaman, L., 1999, A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol, 277(5 Pt 2):R1537-R1540.
58. Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., et al., 1996, Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med, 2(11):1254-1258.
59. Nauck, M.A., Kleine, N., Orskov, C., Holst, J.J., Willms, B., Creutzfeldt, W., 1993, Normalization of fasting hyperglycaemia by exogenous glucagon- like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 36(8):741-744.
60. Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J., 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 359(9309):824-830.
61. Nauck, M.A., Wollschlager, D., Werner, J., Holst, J.J., Orskov, C., Creutzfeldt, W., et al., 1996, Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia, 39(12):1546-1553.
62. Deacon, C.F., Nauck, M.A., Toft-Nielsen, M., Pridal, L., Willms, B., Holst, J.J., 1995, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 44(9):1126-1131.
63. Deacon, C.F., Johnsen, A.H., Holst, J.J., 1995, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 80(3):952-957.
64. Knudsen, L.B., Pridal, L., 1996, Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol, 318(2-3):429-435.
65. Hansen, L., Deacon, C.F., Orskov, C., Holst, J.J., 1999, Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology, 140(11):5356-5363.
66. Wettergren, A., Wojdemann, M., Holst, J.J., 1998, Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol, 275(5 Pt 1):G984-G992.
67. Imeryuz, N., Yegen, B.C., Bozkurt, A., Coskun, T., Villanueva-Penacarrillo, M.L., Ulusoy, N.B., 1997, Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms. Am J Physiol, 273(4 Pt 1):G920-G927.
68. Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., Niijima, A., 1996, Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol, 271(5 Pt 1):E808-E813.
69. Balkan, B., Li, X., 2000, Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol, 279(4):R1449-R1454.
70. Wettergren, A., Wojdemann, M., Meisner, S., Stadil, F., Holst, J.J., 1997, The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut, 40(5):597-601.
71. Wettergren, A., Petersen, H., Orskov, C., Christiansen, J., Sheikh, S.P., Holst, J.J., 1994, Glucagon-like peptide-1 7-36 amide and peptide YY from the L- cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol, 29(6):501-505.
72. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., Holst, J.J., 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50(3):609-613.
73. Holst, J.J., Deacon, C.F., 1998, Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes, 47(11):1663-1670.
74. Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M., Holst, J.J., 1996, Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol, 271(3 Pt 1):E458-E464.
75. Vilsboll, T., Agersoe, H., Krarup, T., Holst, J.J., Similar elimination rates of GLP-1 in obese type diabetic patients and healthy subjects. J Clin Endocrinol Metab., in press.
76. Deacon, C.F., Hughes, T.E., Holst, J.J., 1998, Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes, 47(5):764-769.
77. Ahren, B., Holst, J.J., Martensson, H., Balkan, B., 2000, Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol, 404(1-2):239-245.
78. Pospisilik, J.A., Stafford, S.G., Demuth, H.U., Brownsey, R., Parkhouse, W., Finegood, D.T., et al., 2002, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes, 51(4):943-950.
79. Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.A., et al., 2002, Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 25(5):869-875.
80. Mentlein, R., 1999, Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept, 85(1):9-24.
81. Pederson, R.A., Kieffer, T.J., Pauly, R., Kofod, H., Kwong, J., McIntosh, C.H., 1996, The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism, 45(11):1335-1341.
82. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.M., Pierces, M., Nielsen, P.F., et al., 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A, 97(12):6874-6879.
83. Deacon, C.F., Wamberg, S., Bie, P., Hughes, T.E., Holst, J.J., 2002, Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol, 172(2):355-362.
84. Li, X., Kwasnik, L., Miserendino, R., Mone, M., Hughes, T.E., Vilhauer, E.B., et al., 1997, Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in insulin resistant rats. Diabetes, 46[suppl.1]: 237A.
85. Sudre, B., Broqua, P., White, R.B., Ashworth, D., Evans, D.M., Haigh, R., et al., 2002, Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes, 51(5): 1461-1469.
86. Ritzel, R., Orskov, C., Holst, J.J., Nauck, M.A., 1995, Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia, 38(6):720-725.
87. Rachman, J., Barrow, B.A., Levy, J.C., Turner, R.C., 1997, Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-I) in subjects with NIDDM. Diabetologia, 40(2):205-211.
88. Larsen, J., Hylleberg, B., Ng, K., Damsbo, P., 2001, Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care, 24(8):1416-1421.